Anthropic is leveraging its Claude AI model to accelerate drug development through research partnerships with six organizations, including BigHat Biosciences and Bristol Myers Squibb. The company is also initiating its own drug discovery efforts, focusing on rare childhood diseases. This initiative aims to identify and address bottlenecks throughout the drug development process, from target identification to clinical trial design, with the goal of bringing new medicines to market faster. AI
IMPACT Accelerates the discovery and development of new medicines by identifying and addressing bottlenecks in the drug development pipeline.
RANK_REASON Research update from an AI lab on applying their models to a specific scientific domain.
Read on Mastodon — sigmoid.social →
- Anthropic
- BigHat Biosciences
- Bristol Myers Squibb
- Claude
- Divergence Labs
- Enveda
- Generate:Biomedicines
- The Column Group
AI-generated summary · Google Gemini · from 4 sources. How we write summaries →